United Health chooses Gilead's Harvoni as its preferred hepatitis C treatment over AbbVie's Viekira Pak. Three other huge insurers have done likewise. The battle continues as Express Scripts went with the Viekira Pak. Now, they just have to figure out how to pay for it as both run about $90,000 for a 12 week treatment. SMZ [...]
Amgen Blows out 4th-Q with profits up 27% The amount of wealth you can create in the right stocks is mind boggling. Another Pharma takes off giving investors 167% returns in the last 3 years. Basically, $100,000 invested in AMGN in Feb 2012 is now worth about $270,000. Maybe one can consider Kyprolis and Prolia as [...]
Abilify Patent Expiration sends BMS 2015 top line forecast south. Obviously the street was anticipating the May 2015 expiration of the Abilify patent and for low cost generics to step in; thusly, the shares stay intact. SMZ https://mail.google.com/mail/u/0/#inbox/14b2c84151615a97 Â Â Â
John Martin, Gilead CEO, is getting plugged from everyone, Harvard, Morningstar, Tuck.... The flowers fall on those who perform. GILD shares are up 100 fold in the last 18 years and up 157% in the last two years. Perfect execution!! SMZ
VRX toying with the $158's surely dismisses the myth that they were bullied by Actavis. The price of the stock always tells the tale, whether people want to hear it or not. Surely, closing a deal to merge Valeant and Allergan would have had an interesting upside, but shareholders are not complaining. Additionally, shareholders of [...]
Vertex pulled Incivek, Merck pulls Victrelis, and what will J&J do with the other HEP C compound competing against Gilead and Abbvie? Merck has a few rabbits up their sleeve with a potential approval this year and some M&A, but for now, the battle continues. SMZ
Fastest Growing for now, but what about new competition for Olysio, Zytiga and more? 2015 is going to get squeezed according to the stock chart, which is under major distribution. SMZ
Ouch! This is why I taint the pharma news to the stocks. The Swiss pulled the cap on the Franc and "Kaboom" The Franc rockets to the moon and Swiss shares get a beating. Roche, Novartis, Actelion and Lonza all took a hair cut today. Lonza took it for an 18% bashing today as 90% [...]
Pharma giant cites 2017 use patent in urging docs, pharmacists to stay away January 15, 2015 | By Tracy Staton Usually, when generic copies of a branded drug hit the market, that's the end of the line for scrapping over patent protection. And usually, when drugmakers are trying to protect their patents, they don't go [...]
Novartis Pharmaceuticals has announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients. "By working with Qualcomm Ventures, Novartis sees the opportunity to take a greater leadership role in introducing new mobile or [...]
